G

Genus

Global animal genetics and breeding technology

Internal Controls Specialist

Full-TimeDeadline 9/9/27
£62.5k - £67.5k/yr
Mid
Bachelor's, Certification
Remote in UK
RemoteOccasional travel may be required, with ad hoc visits to Stapeley or Basingstoke.
Risk & ComplianceInternal Audit & Controls

About the job

Requirements
  • A bachelor's degree or professional qualification in accounting, finance, business administration or a related field.
  • Experience conducting control testing and assessments, for example within a listed company, SOX, internal audit, risk, finance or compliance environment.
  • Good understanding of risk assessment methodologies, control design principles and testing techniques.
  • Ability to build effective stakeholder relationships, challenge constructively, and provide clear, practical feedback on control findings and remediation actions.
  • Strong documentation skills, including the ability to prepare clear testing evidence, conclusions and issue summaries that support review and reporting.
  • Experience reviewing or quality assuring the work of others, including peer review of testing documentation, findings and conclusions.
  • Experience using GRC, control testing or similar workflow tools.
  • Ability to work effectively both independently and as part of a team.
  • Strong written and verbal communication skills, including the ability to explain control matters clearly and concisely.
  • Highly organised, with the ability to prioritise work and meet agreed deadlines.
  • Eligibility to work in the UK without requiring a visa or sponsorship.
Responsibilities
  • Plan and execute risk-based design and operating effectiveness testing of material controls, including work required to support UK Corporate Governance Code Provision 29 readiness.
  • Form clear, evidence-based conclusions on control effectiveness, identifying where improvements are required due to evidence gaps, control deficiencies or more fundamental control weaknesses.
  • Provide clear, practical feedback to control owners and other stakeholders on control testing results, including the nature, severity and root cause of findings.
  • Support stakeholders in developing remediation action plans that are proportionate, clearly defined and aligned with the nature of the findings.
  • Work collaboratively with colleagues across the internal controls team to complete, review and document control testing, conclusions and remediation actions consistently and on time.
  • Use GRC technology to document testing activity, record conclusions and track remediation progress, supporting effective oversight and reporting.
  • Contribute to the continuous enhancement of the internal controls framework, with a focus on improving testability, consistency of assessment and transparency of remediation tracking.
  • Ensure project tasks and outcomes are delivered to the agreed scope, time, cost and quality criteria.
  • Make occasional travel based on business need.
Desired Qualifications
  • A relevant professional qualification or certification, for example ACA, ACCA, CIA/IIA or equivalent.
  • Experience using GRC, control testing or similar workflow tools.

About the company

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Genus said 14 July 2026 FY26 results should beat consensus and cut leverage.
  • The Chinese porcine joint venture delivered about £111 million cash in FY26.
  • ABS posted double-digit profit growth in FY26, helped by the Value Acceleration Programme.

What critics are saying

  • North American PIC volumes weakened in FY26 from customer disease challenges.
  • Genus still depends on further approvals before selling PRRS-resistant pigs in Canada.
  • If EU and U.S. adoption stalls, PRRS-resistant pigs stay a stranded platform.

What makes Genus unique

  • PIC’s PRRS-resistant pigs won Canada approval on 23 January 2026.
  • Genus monetizes elite genetics through recurring royalties, not commodity livestock sales.
  • ABS and PIC combine bovine and porcine genetics across 100-plus countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Parental Leave
  • Employee Stock Purchase Plan
  • Paid Holidays
  • Paid Vacation

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT